Results 91 to 100 of about 338,802 (261)

Understanding and Mitigating the Risk of Accelerated Biological Aging in Survivors of Cancer: A Scoping Review

Aging and Cancer, EarlyView.
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi, Emily Herdman, Danielle Westmark, Vijaya R. Bhatt   +3 more
wiley   +1 more source

Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy–Related Inflammation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy–related inflammation (CAA‐RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk. Methods We performed a retrospective cohort study of 36 patients with CAA‐RI treated at the
G. Abbas Kharal, Gowtham Yerneni, Kim J. Griffin, Nicolas Thompson, Ken Uchino, Irene Katzan, Dolora Wisco, Abeer Farrag, Jayashree Sundarajan, Andrew Russman, M. Shazam Hussain   +10 more
wiley   +1 more source

Clinical Impact of MGMT Promoter Methylation in IDH‐Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background The clinical relevance of MGMT promoter methylation in IDH‐mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding.
Haihui Jiang, Linxi Cao, Xiaodong Chen, Siqi Tong, Qinghui Zhu, Jun Yang, Song Lin, Yong Cui   +7 more
wiley   +1 more source

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland

BMC Cancer
Background Immune checkpoint inhibitors (ICIs) have been employed in the adjuvant and metastatic setting of renal cell carcinoma (RCC) treatment. Among ICIs, combined immunotherapy has the highest risk for immune-related adverse events (irAEs).
Renata Pacholczak-Madej, Artur Drobniak, Łukasz Stokłosa, Anna Bidas, Jolanta Dobrzańska, Aleksandra Grela-Wojewoda, Agnieszka Roman, Daria Tusień-Małecka, Jerzy Walocha, Paweł Blecharz, Mirosława Puskulluoglu   +10 more
doaj   +1 more source

Investigation of Remaxol Efficacy in Complex Therapy of Experimental Generalized Tuberculosis on Mice

Антибиотики и Химиотерапия, 2020
Efficacy of remaxol In complex chemotherapy of generalized drug resistant tuberculosis was studied on mice. Mycobacterium tuberculosis 5419 SPBNIIF isolated from a patient with freshey diagnosticated pulmonary tuberculosis resistant to isoniazid (10 mcg ...
D. S. Sukhanov, T. I. Vinogradova, A. V. Elkin, N. V. Zabolotnykh, S. N. Vasilyeva, M. L. Vitovskaya   +5 more
doaj  

Experimental Chemotherapy of Oxyuriasis [PDF]

BMJ, 1953
openaire   +2 more sources

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

Arthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi, Roberta A. Berard, Jean‐Philippe Proulx‐Gauthier, Heinrike Schmeling, Michelle Batthish, Gilles Boire, Adam M. Huber, Dax G. Rumsey, Jaime Guzman, Gaëlle Chédeville, The CAPRI registry Investigators   +10 more
wiley   +1 more source

Iwosydenib w leczeniu chorych na raka dróg żółciowych z obecnością mutacji IDH1 – dane z rzeczywistej praktyki medycznej – badanie wieloośrodkowe.

Oncology in Clinical Practice
Pomimo znacznego postępu, jaki nastąpił w ostatnich latach w leczeniu chorych na nowotwory, rak dróg żółciowych, szczególnie w stadium zaawansowanym, pozostaje w dalszym ciągu chorobą o złym rokowaniu.
Bożena J. Cybulska-Stopa, Maciej Kawecki, Patrycja Szymańska, Piotr Duszyński, Zuzanna Borysiewicz, Marek Szwiec, Cieszymierz Gawiński, Agnieszka Czamańska, Bogumiła Galińska, Paulina Żukowska, Hanna Liberek, Aleksandra Chojnowska, Robert Dziura, Lucjan Wyrwicz, Maciej Krzakowski   +14 more
doaj   +1 more source

3D Bioprinted Glioblastoma Multiforme Models: How the Extracellular Matrix Glycosignature Influences Drug Response

Advanced Functional Materials, EarlyView.
Aberrant glycosylation in the glioblastoma tumor microenvironment drives therapeutic resistance. Here, a 3D bioprinted model was engineered by incorporating α‐NeuNAc‐(2→3)‐β‐D‐Gal‐ and chondroitin sulfate. Combined multiplex immunofluorescence and synchrotron‐based nanoCT analysis revealed that glycan‐matrix interactions dictate specific drug‐escape ...
Francesca Cadamuro, Marco Piazzoni, Ilaria Borghi, Alberto Baeri, Alessandro Fumagalli, Federica Perillo, Hafiz Muhammad Fahad, Martina Ghizzi, Luca Crippa, Gabriella Nicolini, Angela Bentivegna, Daniele Ramazzotti, Valentina Zuliani, Mirko Rivara, Carlo Giorgio Giussani, Andrea Di Cristofori, Guido Cavaletti, Federica Facciotti, Sobhan Sheikhi, Claire Seydoux, Murielle Salome, Peter Cloetens, Alberto Bravin, Paola Coan, Francesco Nicotra, Laura Russo   +25 more
wiley   +1 more source

P1211: CLINICAL HETEROGENEITY OF HIGH-GRADE B-CELL LYMPHOMA. EDGE OF TRANSFORMATION.

HemaSphere, 2022
A. Misyurina, S. Kravchenko, A. Magomedova, A. Kovrigina, T. Obukhova, K. Sychevskaya, E. Zakharko, E. Rubkina, V. Misyurin, F. Babaeva   +9 more
doaj   +1 more source